Eatontown, NJ, Sept., 14 2017. Avet Pharmaceuticals Inc. (“Avet”) announced the immediate availability of Amantadine immediate-release 100mg capsules. This launch adds to Avet’s robust portfolio of generic oral solid products. Amantadine is the AB rated generic equivalent to the antiviral/antiparkinsonian drug Symmetrel®. It is indicated for the treatment of influenza A virus infection and is also indicated in the treatment of Parkinson’s. According to IMS data for the twelve-months ended July 2017, the U.S. market for Amantadine immediate-release capsules is approximately $29.8 million.